Life Science Fund, REHCO, LLC, Presbyterian Health Foundation, together with significant grant funding from the Oklahoma Center for the Advancement of Science & Technology (OCAST) and funding from generous donors worldwide have all played a significant role in moving this research forward. Under the leadership of Stan Hupfeld and then Bruce Lawrence, IBMC’s generous collaborative support established the foundation that led to these breakthroughs. We want to extend a special thank you to other generous donors who made this possible.”

Those supporters include:

• Jasco Giving Hope Foundation
• The Tom L. Ward Family Foundation
• The Meinders Foundation 
• Records-Johnston Family Foundation
• Kimray 
• Charles and Barbara Taylor 
• Pumps of Oklahoma 
• Express Employment Professionals 
• Hough Ear Institute Board of Directors 
• Generous monthly and annual donors worldwide 

About Hough Ear Institute
Hough Ear Institute (HEI) is a nonprofit 501(c)(3) organization committed to restoring hearing worldwide through research, teaching and humanitarian efforts.

About Oblato, Inc.
Oblato, Inc., a wholly-owned subsidiary of the Korean biotech company GtreeBNT, is incorporated in Delaware and has its principal place of business in New Jersey. Since 2016, the company has been developing a new drug, OKN-007, to treat glioblastoma multiforme (GBM). Currently, clinical trials are ongoing to investigate the safety and efficacy of a combination therapy with both OKN-007 and temozolomide for patients with newly diagnosed GBM. The company has lately acquired worldwide exclusive rights of NHPN-1010 for the prevention and treatment of human hearing loss and its relevant diseases, balance disorders, tinnitus and noise induced traumatic brain injury.